Evommune (NYSE:EVMN) Shares Gap Up Following Analyst Upgrade

Evommune, Inc. (NYSE:EVMN)’s share price gapped up before the market opened on Monday after Leerink Partnrs upgraded the stock to a strong-buy rating. The stock had previously closed at $20.71, but opened at $22.83. Evommune shares last traded at $21.18, with a volume of 34,026 shares.

Several other research firms have also recently weighed in on EVMN. Wall Street Zen upgraded shares of Evommune to a “hold” rating in a research report on Thursday, November 20th. Evercore ISI assumed coverage on Evommune in a research report on Monday. They set an “outperform” rating and a $40.00 price target on the stock. William Blair assumed coverage on Evommune in a report on Monday. They issued an “outperform” rating for the company. Cantor Fitzgerald began coverage on Evommune in a research report on Monday. They set an “overweight” rating on the stock. Finally, Leerink Partners assumed coverage on Evommune in a research report on Monday. They issued an “outperform” rating and a $42.00 target price for the company. One analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the stock. According to MarketBeat, Evommune has an average rating of “Buy” and an average target price of $39.33.

Evommune Trading Up 1.2%

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.